- Home
- LENZ
as 07-26-2024 4:00pm EST
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | DEL MAR |
| Market Cap: | 396.0M | IPO Year: | 2021 |
| Target Price: | $31.33 | AVG Volume (30 days): | 177.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $24.84 | Next Earning Date: | 05-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of LENZ Therapeutics Inc. Common Stock (LENZ)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chevallard Daniel R. | LENZ | Chief Financial Officer | May 14 '24 | Buy | $15.68 | 3,188 | $49,987.84 | 3,188 | SEC Form 4 |
| MCCOLLUM JAMES W | LENZ | Director | May 13 '24 | Buy | $15.99 | 31,332 | $501,092.68 | 525,565 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | LENZ | Director10% Owner | Mar 21 '24 | Buy | $15.03 | 64,971 | $976,514.13 | 694,755 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | LENZ | Director10% Owner | Mar 21 '24 | Buy | $15.03 | 933,038 | $14,023,561.14 | 3,319,339 | SEC Form 4 |
Latest LENZ Therapeutics Inc. Common Stock News
LENZ Breaking Stock News: Dive into LENZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
Simply Wall St.
a month ago
We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth
GlobeNewswire
2 months ago
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
GlobeNewswire
2 months ago
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
3 months ago
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
3 months ago
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Business Wire
4 months ago
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Business Wire
4 months ago
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
Compare LENZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LENZ LENZ Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.